jordansmith21

Over the past few decades, biopharmaceuticals have gained significant popularity owing to their therapeutic efficacy, favorable safety profiles and ability to treat a wide variety of disease indications, which are otherwise hard to treat. The success of these interventions has prompted the stakeholders to upgrade the conventional biologics manufacturing equipment. As a result, the domain has witnessed several technological advancements, including the adoption of controllers and automated systems.

Avastin® (bevacizumab) is VEGF-A targeting, humanized monoclonal antibody-based therapeutic developed by Genentech and Roche. It was the first angiogenesis inhibitor drug to be approved by the US FDA. Avastin® was first approved for treatment of advanced colon cancer (2004); since then, the drug has been approved for advanced lung cancers (2006), metastatic breast cancers (2008), kidney cancers and brain (glioblastoma) cancers (2009).

According to the US Food and Drug Administration (FDA), there has been an evident increase in the number of cell and gene therapy products being evaluated in early phases of development. This can further be validated by the observed upsurge in the number of investigational new drug (IND) applications.